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Objective: The purpose of this study was to evaluate the safety and efficacy of a novel endovascular graft for elective
treatment of infrarenal abdominal aortic aneurysm. The device is a modular bifurcated system with nitinol/expanded
polytetrafluoroethylene components and a smaller profile than currently approved devices.
Methods: In a multicenter, concurrent controlled phase II trial, 334 patients underwent treatment with the Excluder
bifurcated endoprosthesis (test, n  235; W. L. Gore & Associates, Inc, Sunnyvale, Calif) or with standard open repair
(control, n  99). Preoperative characteristics, perioperative variables, follow-up clinical evaluations, and radiographic
examination results through the first 2 years were analyzed with univariable and multivariable statistics.
Results: Patients in the test group had less blood loss (310  19 mL versus 1590  124 mL; P < .0001), fewer
homologous transfusions (6% versus 32%; P < .0001), and shorter lengths of stay (2.0  0.1 days versus 9.8  1.4 days;
P < .0001). Early major adverse events were markedly reduced in the test group (14% versus 57%; P < .0001), and this
difference persisted at 2 years. No difference was seen in survival rate (P .13). In the first 2 years, no deployment failure,
early conversion, or aneurysm rupture occurred. At the 2-year timepoint, core laboratory read trunk migration in 1%,
limb migration in 1%, limb narrowing in 1%, endoleak in 20%, and aneurysm growth in 14%. One wire discontinuity
(0.6%) was identified in a discharge film. A 7% annual reintervention rate was seen in the test group in the first 2 years.
Summary: The test device is a safe and effective treatment compared with open surgical repair for infrarenal abdominal
aortic aneurysm. The most striking benefits are reduced blood loss, fewer complications, and faster recovery. Two-year
survival rate was similar. (J Vasc Surg 2003;37:262-71.)
Abdominal aortic aneurysm is a potentially fatal condi-
tion diagnosed in more than 200,000 Americans each year.
There is no proven medical treatment, and surgical repair
has been the only common therapeutic option. Standard
open repair has been associated with significant morbidity
and mortality, prolonged recovery, and some late compli-
cations.1,2 Because of these limitations, many patients and
their physicians choose to defer operative treatment. Re-
cently, endovascular repair has become an alternative, and
some studies favorably compare endovascular repair with
standard open repair.3-10 However, significant concerns
exist about endovascular repair, and its value is the subject
of healthy debate.11-20 Further, it is unknown whether
advances in design technology will produce improved de-
vices with better clinical outcomes. This report describes
the results with a third-generation endovascular device.
METHODS
This report summarizes the results of a US Food and
Drug Administration-approved, multicenter, prospective
trial comparing standard open repair of infrarenal abdomi-
nal aortic aneurysm (control) with test treatment with an
investigational device, the Excluder bifurcated endopros-
thesis (EBE; W. L. Gore & Associates, Inc, Sunnyvale,
Calif). The study was conducted at 19 centers in the United
States, and participating investigators are listed in the Ap-
pendix (online only). Local institutional review boards
approved the study, and all subjects gave informed consent
for participation. Inclusion and exclusion criteria (Table I)
have been previously described.21 The major difference was
that subjects with an adequate infrarenal neck for endovas-
cular repair were assigned to the test group and the control
group required a planned infrarenal clamp. A randomized
trial design was considered by the investigators and was not
used because patients with suitable anatomy for endovas-
cular repair were likely to decline to participate in random-
ization or would withdraw from the study if randomized to
open operation. The primary endpoints were comparison
of major adverse event rates between the two groups at 1
year and assessment of aneurysm exclusion (no endoleak,
aneurysm enlargement, or major device-related complica-
tion) at 1 year. Although the original hypotheses were
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constructed and analyzed according to the 1-year time-
point, available 2-year data were also analyzed for longer
performance. The protocol also specified the following
secondary endpoint comparisons: length of intensive care
unit (ICU) stay, hospital stay, and recovery to normal daily
activities as reported by the research subject. Although
length of stay is related to hospital costs, no formal cost
analysis was performed in this study.
Patients in the control group had standard aneurysmor-
rhaphy through a transperitoneal or retroperitoneal inci-
sion with placement of a sutured fabric graft of physician
choice. For the test group, extensive imaging of the subject
had to be reviewed by the local investigator and then
confirmed by central review until the investigator devel-
oped satisfactory competence. Appropriately sized devices
then were shipped to the investigative site. Test subjects
had bilateral transfemoral access, with endovascular deploy-
ment of the EBE, which has been previously described in
detail.22 Briefly, the EBE is a modular endovascular system
composed of one trunk-ipsilateral piece and one contralat-
eral leg piece (Fig 1). Additional extension cuffs, which are
similarly sized to the aorta (3.3 cm long and 23-mm,
26-mm, and 28.5-mm diameter) and iliac arteries (7 cm
long and 10-mm, 12-mm, and 14.5-mm diameter), are
available. Each stent graft is made of an expanded polytet-
rafluoroethylene (ePTFE) graft material bonded to the
inside of a nitinol exoskeleton with ePTFE/fluorinated
ethylene propylene composite film. Each device is con-
strained with a flexible ePTFE/fluorinated ethylene pro-
pylene sleeve, on a delivery catheter that tracks over a
0.035-in guidewire through 18F (trunk-ipsilateral) and
12F (contralateral leg) sheaths. These size sheaths are
smaller than currently approved devices, and the delivery
system is relatively flexible. Placement is guided with fluo-
roscopic visualization of radioopaque markers, and deploy-
ment is relatively simple with pulling on a deployment line
that releases the constraining sleeve, allowing self expansion
of the stent graft.
Demographic factors, anatomic measurements, periop-
erative parameters, and clinical outcomes were systemati-
cally recorded on case report forms that were verified by a
contract clinical research organization. Adverse events were
stratified by severity into minor or major events with pub-
lished criteria, and this stratification was reviewed by a
Clinical Events Committee.23 Specific criteria for a major
complication were defined in the protocol; for example, the
general category of bleeding included procedural bleeding,
hematoma necessitating reoperation, postoperative bleed-
ing or coagulopathy, and other bleeding complications.
The subcategory of procedural bleeding accounted for the
vast majority of this general category, and this major com-
plication required at least 1000-mL blood loss and inter-
vention, such as transfusion or reoperation. Earlier report-
ing standards were used when applicable because the more
recent reporting standards criteria were not available at the
initiation of this trial.24-27 Periodic clinical and radio-
graphic follow-up is necessary after endovascular repair.28
Control patients received a physical examination and ankle
brachial index reading at discharge, 1 month, 6 months,
and 12 months and annually thereafter and a computed
tomographic (CT) scan at 12 months and annually there-
after. Test patients received a physical examination and
Table I. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Infrarenal AAA  4.5 cm in diameter 1. Mycotic or ruptured aneurysm
2. Infrarenal aortic neck length  15 mm (test); able to
receive infrarenal clamp (control)
2. Participating in another investigational device or drug study
within 1 y
3. Anatomy meets EBE specification criteria (test only) 3. Documented history of drug abuse within 6 mo
4. Access vessel able to receive 18F introducer sheath 4. Coexisting thoracic aortic aneurysm (50% larger than aorta
proximal to aneurysm)
5. Life expectancy  2 y 5. Myocardial infarction or cerebral vascular accident within 6 wk
6. Surgical candidate 6. Pulmonary insufficiency requiring chronic home oxygen therapy
or inability to ambulate due to pulmonary function
7. ASA class I, II, III or IV 7. Renal insufficiency (creatinine  2.5 mg/dL) without dialysis
8. NYHA class I, II, or III 8. Iliac anatomy that would require occlusion of both internal iliac
arteries
9. Male or infertile female 9. “Planned” occlusion or reimplantation of significant mesenteric
or renal arteries
10. 21 y of age or older 10. “Planned” concomitant surgical procedure or previous major
surgery within 30 d
11. Ability to comply with protocol requirements including
follow-up
11. Proximal neck angulation  60 degrees (test only)
12. Signed informed consent form 12. Presence of significant thrombus at arterial implantation sites
(test only)
13. Previous prosthesis placement in same position of aorta or iliac
arteries
14. Degenerative connective tissue disease (eg, Marfan and Ehlers-
Danlos syndromes)
Unless otherwise noted, criteria applied to both control and test groups.
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; NYHA, New York Heart Association.
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ankle brachial index reading at discharge, 1 month, 6
months, and 12 months and annually thereafter and CT
scan at 1 month, 3 months (if endoleak was present at 1
month), 6 months, and 12 months and annually thereafter
and plain radiographs at discharge, 6 months, and 12
months and annually thereafter. Radiographic studies were
overread by a central corelab (Cleveland Clinic). The fol-
lowing guidelines for reintervention were prescribed: aneu-
rysms with type I endoleak, type III endoleak, or enlarge-
ment (regardless of endoleak status) would be intensively
studied and considered for reintervention or conversion to
open repair. This consideration would include the local
principal investigator’s and attending physician’s assess-
ment of an individual subject’s comorbidities, life expect-
ancy, and, of course, the subject’s personal choices.
For this publication, members of the writing group
personally reviewed case report forms, selected source doc-
uments, and conducted the statistical analysis and interpre-
tation. Specifically, each author was involved in data acqui-
sition/analysis, had full access to all data, helped write the
article, selected where and when the report was submitted,
and approved the final version. Each site principal investi-
gator was involved in study design, proper conduct of the
trial, and data collection. Each subinvestigator was involved
in data acquisition. The sponsor reviewed the paper only for
proprietary information and technical accuracy, and the
writing group retained final review authority.
Statistics. It was anticipated that 234 subjects would
need to be analyzed at 1 year to obtain 80%power to detect
if the test was associated with 15% fewer major complica-
tions at a P value of .05. A total of 334 patients were
enrolled on the basis of anticipated subject attrition (with-
drawal, loss to follow-up, death, and initial training). De-
scriptive statistics are listed as mean  one standard error.
Kaplan-Meier curves were used to depict event frequencies
over time, and error bars represent  10%; a dotted line
indicates the standard error is more than 10%. Comparisons
of Kaplan-Meier curves were done with the log-rank test.
Comparisons of continuous variables were done with two-
tailed t tests, and discrete variables were compared with 2
and Fisher exact tests. Cox proportional hazards multivari-
able regression was used for analysis of potential indepen-
dent risk factors.
RESULTS
Ninety-nine subjects were enrolled in the control
group, and 235 in the test group. Analysis determined
minimal significant differences between sites and between
the first two (training) test patients at each site and later
patients, so all subjects were pooled together for all subse-
quent analyses. Table II compares preprocedural variables
between the two groups. More than 30 additional medical
history and more than 40 additional anatomic variables
were compared that were not significantly different. Gen-
erally, the control and test groups were comparable in most
clinical variables at baseline. However, with univariate anal-
ysis, the control group was younger, was composed of more
women, had lower hyperlipidemia scores, had lower serum
blood urea nitrogen and creatinine levels, and had more
symptomatic aneurysms. The Society for Vascular Surgery
risk factor score showed a slightly greater total severity of
preexisting comorbidities in the test group, but this was not
statistically significant (P  .425).25 There were several
anatomic differences between the groups; the control
group had larger aneurysms, larger common iliac artery
measurements, and shorter, wider, and more angulated
proximal necks.
Fig 1. EBE components. From top to bottom, aortic extender, main trunk-ipsilateral leg, contralateral leg, and iliac
extender.
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All control patients underwent successful repair, 53%
with a bifurcated graft and 47% with a tube graft. Ninety
percent had an infrarenal aortic clamp, and 10% had a
suprarenal aortic clamp. In the test group, 100% of the
patients had successful deployment of the trunk-ipsilateral
leg and contralateral leg; 33% had one or more extenders.
Procedural variables and recovery are summarized in Table
III. Compared with the control group, the test group had
substantially less blood loss, less chance of homologous
blood transfusion, less recovery time (ICU stay, time to eat,
time to walk, hospital stay), and less complete recovery time
(likelihood of and time to return to normal activity).
Table IV shows the types of early major adverse events
by organ system. The test group comparative safety was
primarily in bleeding, pulmonary, cardiac, bowel, and vas-
cular complications. No difference was seen in renal com-
plications. Freedom from a first major complication, cumu-
lative major adverse events, and linearized rates of major
adverse events are depicted in Figs 2 to 4. Fig 2 shows that
the test cohort had a lower chance of any major complica-
Table II. Significantly different pretreatment variables
Variable Control Test P value
Age (y) 70.1  0.8 73.0  0.5 .002
Gender
Male 73 (74%) 204 (87%) .004
Female 26 (26%) 31 (13%)
Medical history
Symptomatic AAA
Yes 15 (15%) 11 (5%) .001
No 83 (85%) 224 (94%)
Hyperlipidemia
Yes 38 (38%) 116 (49%) .018
No 50 (51%) 83 (35%)
Missing 11 (11%) 36 (15%)
Laboratory values
BUN (mg/dL) 17.8  0.8 19.5  0.5 .047
Creatinine (mg/dL) 1.07  0.04 1.16  0.02 .029
Aortic morphology
AAA diameter (mm) 58.6  1.09 55.6  0.61 .01
Aortic neck length (mm) 20.5  1.47 28.9  0.73 .0001
Aortic neck angulation (degrees) 35.8  3.78 22.0  1.05 .0001
Aortic neck diameter (mm) 24.0  0.38 22.3  0.14 .0001
Right common iliac diameter (mm) 14.1  0.74 12.4  0.19 .03
Left common iliac diameter (mm) 13.3  0.63 11.8  0.15 .02
AAA, Abdominal aortic aneurysm; BUN, blood urea nitrogen.
Table III. Procedural outcomes
Procedural characteristics Control Test P value
Location .0001
Operating room 99 (100%) 194 (83%)
Angiography suite 0 41 (17%)
Anesthesia .0001
Local 0 8 (3%) .0001
Regional 2 (2%) 87 (37%)
General 97 (98%) 140 (60%)
Anesthesia time (min) 283  9 221  4 .0001
Procedure time (min) 196  8 144  3 .0001
Blood loss and replacement
Blood loss (mL) 1590  124 310  19 .0001
Homologous transfusion frequency 32 (32%) 15 (6%) .0001
Recovery outcomes
ICU stay .0001
Yes 86 (87%) 56 (24%)
No 13 (13%) 179 (76%)
ICU stay (h) 67  19.9 6  0.8 .0001
Hospital length of stay (d) 9.8  1.4 2.0  0.1 .0001
Time to first oral intake (d) 2.6  0.2 0.5  0.0 .0001
Time to ambulation (d) 2.6  0.2 1.0  0.0 .0001
Time to return to normal activity (d) 92  12 42  4 .002
Percent with incomplete recovery at 6 mo 20% 5%
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tion. These Kaplan-Meier curves portray freedom from the
first major adverse event, and therefore fewer control sub-
jects are at risk for a first event after 30 days. Fig 3 shows
that there were fewer complications per patient in the test
group. Fig 3 also shows that after the periprocedural differ-
ence in major adverse events, the curves become parallel,
indicating similar rates of subsequent events. Fig 4 shows
that these benefits were manifest in the early follow-up
period. At 1 year of follow-up, including early and late
events, freedom from major complications remained signif-
icantly different (36% control versus 67% test; P  .0001).
At 2 years of follow-up, freedom from major complications
remained significantly different (33% control versus 53%
test; P  .0001).
Analysis of major, minor, and total complications is
important to evaluate whether application of the Sacks
criteria may obscure differences in the two groups.23 The
rates of freedom from early (30 days) minor complica-
tions were 36% for the control group and 66% for the test
group; freedom from any early major or minor adverse
event was 12% for the control group and 59% for the test
group. Both of these rates were significantly reduced in the
endovascular group, indicating that the safety benefit of the
test group was present regardless of the stratification by
severity.
In order to evaluate the effects of differences in baseline
variables and the unexpectedly high 10% of control patients
who needed suprarenal clamping, multivariable analysis was
performed. Independent predictors of early major adverse
events were history of myocardial infarction, history of
prior thrombotic event, higher Society for Vascular Surgery
pulmonary risk score, and lower baseline platelet counts.
Further, the control treatment group remained a statisti-
cally significant independent predictor of more major com-
plications, with a strikingly high odds ratio (hazards ratio,
12.018; 95% CI, 6.442 to 22.421; P .0001). In addition,
if patients with suprarenal clamp were excluded from the
control group, there was still a striking reduction in early
major adverse events, from 54% in control subjects to 14%
in the test group (P .0001). Similar multivariable analysis
of later major adverse events showed that the treatment
group was not a risk factor from 30 days to 14 months
(hazards ratio, 1.271; 95% CI, 0.759 to 2.129; P  .362)
and from 30 days to 28 months (hazards ratio, 1.241; 95%
CI, 0.794 to 1.941; P  .343). These results confirm the
findings of the univariate analysis.
Survival curves for the two groups are depicted in Fig 5.
Most deaths were from cardiac causes and cancer. None of
the deaths were related to device or graft failure or aneu-
rysm rupture. The survival rate was 95% in the control
group versus 94% in the test group at 1 year and 93% in the
control group versus 87% in the test group at 2 years. No
significant difference was seen in survival rate between the
two groups with univariable (P  .13, log-rank test) or
multivariable (hazards ratio, 1.448; 95% CI, 0.625 to
3.354; P  .388) analysis.
Table V shows the corelab-determined radiographic
findings at 1 and 2 years. The endoleak rate was 17% at 1
year and 20% at 2 years. The vast majority were type II
endoleaks.29 During the first year, corelab reported 14% of
aneurysms shrinking 5 mm or more and 7% enlarging by 5
mm or more. During the first 2 years, corelab reported 19%
of aneurysms shrinking 5 mm or more and 14% enlarging
by 5 mm or more. There were significantly more (P .004)
endoleaks in the group of enlarging aneurysms compared
with aneurysms that were unchanged in size and shrinking
aneurysms.
Aneurysm reintervention was necessary in 17 patients
(7%) during the first year and on 14 patients (7%) during
the second year, and all but four of these reinterventions
were endovascular (Table VI). Eighty-eight percent were
judged to be successful by the investigator. Three of these
reinterventions were for the four major device-related com-
plications; one patient had immediate trunk migration after
deployment (in a highly angulated proximal neck) that was
treated with an aortic extender, one patient had an iliorenal
bypass for an occluded renal artery at 5 weeks (occlusion
suspected at initial placement), and one patient had two
aortic extenders placed for an increase in proximal neck
angulation and neck diameter in the second year. A fourth
patient had inadvertent occlusion of a hypogastric artery
that was associated with long-term buttock claudication
and did not undergo reintervention. The rest of the rein-
terventions were performed to seal an endoleak or to ad-
dress abdominal aortic aneurysm growth and included
three elective late open conversions. No aneurysm ruptures
have occurred.
The three patients who underwent conversion all had
enlarging aneurysms, and none had any previous reinter-
vention. The first patient had no endoleak identified in the
24 months before conversion, and no conclusive endoleak
was shown on intraoperative examination with the sac
open. The second patient underwent conversion after 29
months; no endoleak was seen, and the patient appeared to
have endotension from proximal neck dilation with conti-
nuity between the aortic lumen and aneurysm thrombus.
The third patient had conversion at 28 months after declin-
ing catheter-based embolization for type II endoleak.
When test patients underwent conversion to open repair,
Table IV. Early major adverse events
Control Test P value
Any major adverse event 57% 14% .0001
Bleeding complications 32% 4% .0001
Pulmonary complications 12% 1% .0001
Cardiac complications 14% 3% .0001
Renal function complications 3% 1% .16
Wound complications 4% 3% .75
Bowel complications 16% 2% .0001
Vascular complications 6% 1% .02
Neurologic complications 2% 0.4% .21
Genitourinary 1% 0.4% .51
Neoplasm 0% 0.4% .99
30-d mortality rate 0% 1% NS
NS, Not significant.
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complications continued to be attributed to the test group;
specifically, analysis continued according to the original
intent-to-treat group assignment.
At the 2-year timepoint, corelab frequency of trunk
migration was 1%, limb migration was 1%, and limb nar-
rowing was 1%. None of the subjects with radiographic
migration or narrowing had type I or III endoleaks, aneu-
rysm enlargement, or reintervention. There was one wire
discontinuity identified in a discharge film of one subject
(0.6%). This patient had no endoleak, migration, or nar-
rowing, and the aneurysm shrunk at 12 months. However,
no other plain radiographs were performed before the
patient died of inoperable liver cancer after the first year.
Sites reported similar 1-year and 2-year endoleak rates
of 16% and 15% and aneurysm shrinkage rates of 24% and
25% but lower rates of aneurysm enlargement, 3% and 10%,
respectively. Sites reported lower incidence rates of other
radiographic complications and no wire fractures.
DISCUSSION
Endovascular repair of aortic aneurysms is associated
with a markedly lower morbidity compared with standard
open repair. The primary safety outcome measurement,
major adverse events, was analyzed in several ways. Com-
pared with the control group, test subjects had both a
reduction in chance of any major complication and a lower
Fig 2. Kaplan-Meier curves show freedom from first major adverse event. Control (squares) and test (circles) curves
diverge rapidly.
Fig 3. Curves show cumulative major adverse event rates. Control (squares) and test (circles) curves diverge rap-
idly.
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average number of complications per patient. These reduc-
tions were manifest in the first postoperative month. Lin-
earized rates showed that there was no subsequent in-
creased risk of major adverse events, even with
consideration of reintervention as an adverse event.23
However, there is an ongoing frequency of subsequent
events unrelated to abdominal aortic aneurysm treatment
that leads to progressive mitigation of the early difference in
freedom from the first major adverse event. This has been
noted in other studies of longer follow-up duration and is
useful in patient counseling.3
Caution is warranted in any study that is not random-
ized because selection bias could contribute to these differ-
ences. For example, the test group had greater severity of
Fig 4. Bar graph of linearized major adverse event rates. Control (open bars) and test (black bars) are similar after early
period.
Fig 5. Kaplan-Meier curves show survival by group; control (squares) and test (circles) curves overlap. No deaths
occurred from aneurysm rupture.
Table V. Endoleak rates and locations
Endoleak status 1 mo (n  180) 12 mo (n  156) 24 mo (n  119)
No endoleak 141 (78%) 129 (83%) 95 (80%)
Type I 7 (4%) 2 (1%) 3 (3%)
Type II 21 (12%) 19 (12%) 16 (13%)
Type III 0 0 0
Type IV 0 0 0
Indeterminate 11 (6%) 6 (4%) 5 (4%)
Total 39 (22%) 27 (17%) 24 (20%)
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important risk factors, including older age and worse base-
line renal function. On the other hand, fewer symptomatic
aneurysms were seen in the test group, possibly because of
the lag time needed to review imaging and implement
proposed treatment. It should be noted that neither group
included ruptured or infected aneurysms. Interestingly,
female gender, which was more prominent in the control
group, was not an independent risk factor for early or late
adverse events in this study. Finally, aneurysm morphology
was more extensive in the control group, although much of
this was from the anatomic requirements for the endovas-
cular repair. The multivariable analysis was undertaken to
analyze the effects of these pretreatment differences and
showed that the test treatment group remained a highly
significant independent predictor of fewer major adverse
events, with a remarkable 12-fold relative risk reduction.
Endovascular repair has been associated with delayed
complications of aneurysm rupture, and long-term fol-
low-up has been considered mandatory.30-33 There is con-
cern that late aneurysm rupture could significantly exceed
the rates after open repair and eradicate any short-term
benefits with the endovascular option. Corelab imaging
findings may be surrogates of future clinical adverse events.
The endoleak rate in this study was comparable with other
series, and most of these leaks were classified as type II. The
significance of endoleaks is not completely defined, al-
though this study found an association with differential
aneurysm size change.14,34,35 However, endoleak was not
an independent predictor of adverse events or survival,
which may be because of the reintervention guidelines
recommended in this trial. Other corelab surrogate findings
occurred at low frequency and had rare clinical sequelae.
Specifically, there was no limb dislocation associated with
limb migration, no limb occlusions, and no clinical conse-
quences related to wire discontinuity. The etiology of wire
discontinuity on the discharge imaging is unclear. High
sensitivity and continuous refinement of radiographic im-
aging is important because fatigue-related wire fractures
have been found in many abdominal aortic aneurysm en-
dografts with longer follow-up.
The reintervention rate in this study was 7% during the
first year and 7% during the second year, and most of these
cases were endovascular procedures. This rate compares
favorably with other series that report approximately 11%
conversion and secondary intervention rates at 2 years and
30% early conversion, late conversion, and secondary inter-
vention rates at 3 years.3,5,8 Clearly, there are differences in
the frequency and types of complications, requirements for
follow-up, and reinterventions with various device designs.
Nonetheless, this analysis suggests that the early safety
benefits are not erased by the need for late reinterventions
out to 2 years, and longer term analysis is planned for the
EBE test group.
Radiographic imaging after standard open repair has
shown that as many as 25% of patients may have subsequent
complications develop, such as hernias and subsequent
aneurysms, that may necessitate surgical reintervention.
These late complications are often delayed by several years
or decades.2,36-38 Unfortunately, few device trials have
followed control patients radiographically for long periods,
and there is less assurance that the literature-based patient
groups are comparable. In an analysis of one endograft trial,
CT scan follow-up of control patients found abdominal
wall defects in 20% and renal mass loss in 26% at 5 years.39
Clearly, there is both scientific and patient safety rationale
for radiographic surveillance of the control group.
In analysis of secondary endpoints, test group recovery
is more rapid, with fewer ICU stays, faster return of bowel
function and ambulation, shorter hospitalization, and more
rapid recovery to full function. These short-term benefits
are important considerations to the elderly population at
risk for abdominal aortic aneurysms. Not only do many
patients lead active lives and seek effective treatments with
minimal discomfort and faster recovery, but the families
responsible for assisting the recovery are interested in the
duration of recovery and real risks for long-term loss of
function.1 This study documented a 50% reduction in total
recovery time and a significantly improved chance of abso-
lute recovery at 6 months after the procedure from 80%
with control to 95% with the test treatment.
Comparison of various endovascular devices is difficult
because of differences in definitions of major adverse
events, and this study was not designed for that purpose.
However, complications of limb occlusion, iliac injury, and
renal dysfunction were infrequent with this newer design.
There were no early conversions in this EBE series. This
could be attributed to experienced clinician investigators,
adherence to stringent selection criteria, or specific charac-
teristics of the EBE device: stent grafts that fully supported
the entire length, smaller deployment sheaths, flexible de-
livery systems, and a simple deployment procedure. Defin-
itive comparative studies are unlikely to be performed be-
cause of the different eligibility criteria for each device.
Table VI. Reinterventions during first 2 years and any conversions
No. of reinterventions Type Reason
3 Aortic extenders or iliorenal bypass Device-related complication (see text)
25 Embolization Endoleak or AAA growth
1 Ligation Endoleak and AAA growth
3 Conversion Endoleak or AAA growth (see text)
AAA, Abdominal aortic aneurysm.
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CONCLUSION
Endovascular repair of abdominal aortic aneurysms
with this newer stent graft device is associated with a
striking reduction in recovery time and complication rates.
Reduced adverse events persist through the first 2 years
after repair. Similar to other endografts, clinical and radio-
graphic surveillance is necessary to identify those patients
who may need reintervention to reduce the rare risk of
aneurysm rupture. Analysis of longer follow-up is planned
to assess the comparative durability of this device with
standard open repair.
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DISCUSSION
Dr Peter R. F. Bell (Leicester, United Kingdom). Could I
suggest an alternative conclusion to you. You have merely shown
that statistics can give whatever answer you want. How could you
compare a group that has six suprarenal clampings with a group
that hasn’t any?
Secondly, I can tell you from the EVAR trial in the UK, that
we only randomize after we have shown that the patient is suitable
for endovascular repair. These patients do extremely well after
open surgery, which is an easy operation, using a straight graft with
no blood loss and home in 4 days. May I suggest that you are not
comparing like with like, you are comparing oranges with rhinoc-
eroses.
Dr Jon S. Matsumura. I think that there are limitations to a
nonrandomized study, as we do have pretreatment differences.
Our analysis and interpretation of this data involved standard,
accepted statistics.
In the univariable analysis, if you exclude those patients who
had a suprarenal clamp, the findings are similar. Further, we used a
Cox proportional hazards model that included all pretreatment
anatomic and nonanatomic variables. There were more indepen-
dent risk factors distributed in the test group, and the multivariable
risk-adjusted odds ratio was greater—specifically, a 12-fold in-
creased risk of early major adverse events in the control group.
Dr William C. Krupski (Denver, Colo). I have two ques-
tions. First, how many patients in the control group were candi-
dates for endografts?
Second, do you feel confident enough about this device to use
it to repair aneurysms in young, good-risk patients?
Dr Matsumura. Some anatomic criteria allowed enrollment
in the control group and excluded subjects from the test group.
Other anatomic variables and all nonanatomic inclusion criteria
were the same in both groups. I do not know exactly how many
control patients were not endograft candidates.
I do not feel very confident using any endograft in a 60-year-
old patient, whom I anticipate is going to live for a long time.
Having said that, I think there are some patients who, after
you present them statistics on reinterventions, late conversions,
and the fact that we do not know what precisely happens in the
long term, still will choose the endovascular therapy. I try to extract
a promise from them that they will follow-up and expect that we
will be reintervening in many patients.
Dr Piergiorgo Cao (Perugia, Italy). I have just one question.
You presented a 14% diameter increase after 2 years and only a 19%
diameter regression on the same interval. This appears to be quite
a high rate of aneurysm expansion in a relatively small interval.
How many were related to endoleak? And in those that were not,
do you have any hypothesis on those results, like the possibility of
some interaction between PTFE and aneurysm intrasac pressure?
Dr Matsumura. I do not know why they do not shrink as fast
as reported after some grafts. Other investigators have presented
specific data on this topic today. Personally, I have always believed
that there is a statistical relationship between endoleak and aneu-
rysm growth or slower aneurysm shrinkage.
Dr Jeffrey L. Ballard (Loma Linda, Calif). Were the control
patients transperitoneal aortic exposures?
Dr Matsumura. Yes.
Dr Ballard. Well, then I really do not think this is a fair
comparison. It would be instructive to see data that compare
endografts with retroperitoneal aortic surgery because that is our
best open operation. I suspect that your open surgery complication
rate would drop dramatically if you compared retroperitoneal cases
with your endografts. Could you comment on that thought?
Dr Matsumura. Well, my own preference now is the mini-
mally invasive transperitoneal approach that Dr Turnipseed has
popularized. So, I agree that what we consider a control group, our
open operation, continues to improve through 2002.
I would submit, however, that there are newer techniques in
the endovascular group that may have improved results. I think we
all welcome the European trials and the VA trial that will compare
these advances. However, I do not believe there is a trial that
permits only retroperitoneal approach for controls.
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